(Q37777482)

English

HIV and bone disease

scientific article published on November 1, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1 reference

Europe PubMed Central

HIV and bone disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

0 references

Eugene V McCloskey

4

object named as

Eugene McCloskey

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

David H Dockrell

2

object named as

David Dockrell

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682280

16 June 2024

author name string

Benjamin Stone

1

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Christine Bowman

3

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Eugene McCloskey

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682280

16 June 2024

language of work or name

0 references

publication date

1 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1 November 2010

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20682280

16 June 2024

number of pages

12

1 reference

based on heuristic

inferred from page(s)

full work available at URL

https://api.elsevier.com/content/article/PII:S0003986110003085?httpAccept=text/xml

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

https://api.elsevier.com/content/article/PII:S0003986110003085?httpAccept=text/plain

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Archives of Biochemistry and Biophysics

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

503

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

66-77

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Improved survival in HIV-infected persons: consequences and perspectives

3

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

4

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

CD4+ count-guided interruption of antiretroviral treatment

5

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

6

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Bone disease and HIV infection

7

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy

8

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Osteopenia in HIV-infected patients: is it the disease or is it the treatment?

9

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Reduced bone mineral density in HIV-positive individuals

10

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

11

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Osteopenia in patients infected by the human immunodeficiency virus. A case control study

12

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients

14

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

15

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Osteopenia in HIV-infected women prior to highly active antiretroviral therapy

16

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Bone mass in HIV-infected patients: focus on the role of therapy and sex.

17

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

BMD Is Reduced in HIV-Infected Men Irrespective of Treatment

18

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia

19

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Reduced bone density in HIV-infected women

20

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients

22

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Bone mass and mineral metabolism in HIV+ postmenopausal women

23

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Potential predictive factors of osteoporosis in HIV-positive subjects

24

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Abnormalities in the bone mineral metabolism in HIV-infected patients

25

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Reduced bone mineral density in HIV-infected patients: prevalence and associated factors

26

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study

27

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

28

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

29

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection

31

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

33

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

34

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Assessment of fracture risk

35

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Effects of chronic heroin abuse on bone and mineral metabolism

36

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Chronic toxicology of cannabis

37

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo

38

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?

39

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study

40

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Smoking cessation in HIV patients: rate of success and associated factors.

41

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease

42

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States

43

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Causal considerations on alcohol and HIV/AIDS--a systematic review

46

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Polysubstance use and HIV/STD risk behavior among Massachusetts men who have sex with men accessing Department of Public Health mobile van services: implications for intervention development

48

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.

49

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings

50

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the

51

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Endocrine disorders in men infected with human immunodeficiency virus

52

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

The Journal of Clinical Endocrinology and Metabolism

53

81

4108

author name string

Dobs

publication date

1996

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy

54

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome

55

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Longitudinal analysis of bone density in human immunodeficiency virus-infected women

56

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study

60

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

61

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men

62

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors

64

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation

65

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS.

66

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

The Journal of Clinical Endocrinology and Metabolism

67

84

145

author name string

Aukrust

publication date

1999

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

A TH1-->TH2 switch is a critical step in the etiology of HIV infection

68

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ

69

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men

71

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity

72

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk

73

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

74

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells

75

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.

76

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation

77

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src

78

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development.

79

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects

81

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Short-term bone loss in HIV-infected premenopausal women

82

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years

83

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Continuous antiretroviral therapy decreases bone mineral density

84

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

85

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.

86

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

87

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

88

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

89

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.

90

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.

91

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts

92

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Select HIV protease inhibitors alter bone and fat metabolism ex vivo

93

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling

94

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss

95

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents

96

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

AZT enhances osteoclastogenesis and bone loss

97

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Antiretroviral nucleoside and nucleotide analogues and mitochondria

98

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss

99

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts

100

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Effect of tenofovir on renal glomerular and tubular function

101

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Tenofovir-associated renal and bone toxicity

102

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

103

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Journal of Acquired Immune Deficiency Syndromes

104

38

301

author name string

Day

publication date

2005

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

105

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N

106

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Population pharmacokinetic meta-analysis with efavirenz

107

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

The Journal of Clinical Endocrinology and Metabolism

108

83

3050

author name string

McNurlan

publication date

1998

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

109

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

110

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides

111

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy

112

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy

113

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women

114

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

How important are BMD accuracy errors for the clinical interpretation of DXA scans?

115

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

DXA in vivo BMD methodology: an erroneous and misleading research and clinical gauge of bone mineral status, bone fragility, and bone remodelling

116

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

FRAX and the assessment of fracture probability in men and women from the UK

117

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

FRAX and its applications to clinical practice

118

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

BMD, clinical risk factors and their combination for hip fracture prevention

119

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

120

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

121

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

122

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

123

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist

124

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

126

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection

127

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.

128

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis

129

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial

130

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

The Journal of Clinical Endocrinology and Metabolism

132

86

2020

author name string

Fairfield

publication date

2001

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial

133

1 reference

10.1016/J.ABB.2010.07.029

https://api.crossref.org/works/10.1016/J.ABB.2010.07.029

16 June 2024

Identifiers

10.1016/J.ABB.2010.07.029

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

release_o3hkwvdlfjavfptdmlh3j5c2ae

1 reference

https://api.fatcat.wiki/v0/release/o3hkwvdlfjavfptdmlh3j5c2ae

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37777482&oldid=2180992215"